126 related articles for article (PubMed ID: 9163863)
1. A pharmacokinetic comparison of the corn oil versus microemulsion gelcap formulation of cyclosporin used de novo after renal transplantation.
Amante AJ; Meier-Kriesche HU; Schoenberg L; Kahan BD
Transpl Int; 1997; 10(3):217-22. PubMed ID: 9163863
[TBL] [Abstract][Full Text] [Related]
2. Pretransplant test-dose pharmacokinetic profiles: cyclosporine microemulsion versus corn oil-based soft gel capsule formulation.
Chueh SC; Kahan BD
J Am Soc Nephrol; 1998 Feb; 9(2):297-304. PubMed ID: 9527407
[TBL] [Abstract][Full Text] [Related]
3. Oral cyclosporine preparations immediately following renal transplantation.
Katz SM; Amante A; Schoenberg L; Kahan BD
Transplant Proc; 1996 Aug; 28(4):2164. PubMed ID: 8769188
[TBL] [Abstract][Full Text] [Related]
4. Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation.
Kovarik JM; Mueller EA; Richard F; Niese D; Halloran PF; Jeffery J; Paul LC; Keown PA
Transplantation; 1996 Sep; 62(6):759-63. PubMed ID: 8824473
[TBL] [Abstract][Full Text] [Related]
5. Pre- and postrenal transplantation pharmacokinetics of cyclosporine microemulsion.
Talaulikar GS; John GT; Selvakumar R; Job V; Thomas PP; Jacob CK
Transplant Proc; 2003 Jun; 35(4):1295-7. PubMed ID: 12826141
[TBL] [Abstract][Full Text] [Related]
6. Influence of bile on cyclosporin absorption from microemulsion formulation in primary liver transplant recipients.
Winkler M; Ringe B; Oldhafer K; Kattner A; Färber L; Maibücher A; Wonigeit K; Pichlmayr R
Transpl Int; 1995; 8(4):324-6. PubMed ID: 7546157
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Neoral and Sandimmun for induction and maintenance immunosuppression after kidney transplantation.
Senel FM; Yildirim S; Karakayali H; Moray G; Haberal M
Transpl Int; 1997; 10(5):357-61. PubMed ID: 9287400
[TBL] [Abstract][Full Text] [Related]
8. Cyclosporin microemulsion (Neoral). A pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation.
Coukell AJ; Plosker GL
Pharmacoeconomics; 1998 Dec; 14(6):691-708. PubMed ID: 10346420
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetic model to predict steady-state exposure to once-daily cyclosporin microemulsion in renal transplant recipients.
Schädeli F; Marti HP; Frey FJ; Uehlinger DE
Clin Pharmacokinet; 2002; 41(1):59-69. PubMed ID: 11825097
[TBL] [Abstract][Full Text] [Related]
10. Concentration-guided strategies in drug development: experience with a cyclosporine analog in transplantation.
Kovarik JM; Mueller EA; Kallay Z; Smith HT; Lison AE; Arns W; Renner E
J Clin Pharmacol; 1995 Dec; 35(12):1136-43. PubMed ID: 8750363
[TBL] [Abstract][Full Text] [Related]
11. Preprandial microemulsion cyclosporine administration is effective for patients with refractory nephrotic syndrome.
Shirai S; Yasuda T; Tsuchida H; Kuboshima S; Konno Y; Shima Y; Sato T; Hatta S; Masuhara K; Kimura K
Clin Exp Nephrol; 2009 Apr; 13(2):123-129. PubMed ID: 19057979
[TBL] [Abstract][Full Text] [Related]
12. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals.
Kahan BD; Dunn J; Fitts C; Van Buren D; Wombolt D; Pollak R; Carson R; Alexander JW; Choc M; Wong R
Transplantation; 1995 Feb; 59(4):505-11. PubMed ID: 7878754
[TBL] [Abstract][Full Text] [Related]
13. The impact of (1:1) cyclosporine A conversion to its microemulsion formulation on the kidney function of patients with cardiac allografts.
Khajehdehi P; Yip D; Bastani B
Clin Transplant; 1999 Apr; 13(2):176-80. PubMed ID: 10202614
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).
Noble S; Markham A
Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033
[TBL] [Abstract][Full Text] [Related]
15. Equivalence of cyclosporine blood level assays in patients receiving cyclosporine microemulsion or cyclosporine. The Sandoz Neoral Study Group N103.
Pescovitz MD; Wong RL; Choc MG; Chang CT
Clin Transplant; 1997 Oct; 11(5 Pt 1):442-5. PubMed ID: 9361938
[TBL] [Abstract][Full Text] [Related]
16. Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group.
Hoyer PF
Pediatr Transplant; 1998 Feb; 2(1):35-9. PubMed ID: 10084758
[TBL] [Abstract][Full Text] [Related]
17. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral.
Ritschel WA
Clin Transplant; 1996 Aug; 10(4):364-73. PubMed ID: 8884110
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic conversion study of a new cyclosporine formulation in stable adult renal transplant recipients.
Perlík F; Masri MA; Rost M; Kamarád V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Dec; 149(2):309-13. PubMed ID: 16601778
[TBL] [Abstract][Full Text] [Related]
19. Substitution of conventional cyclosporin with a new microemulsion formulation in renal transplant patients: results after 1 year.
Neumayer HH; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Budde K; Waiser J; Luft FC
Nephrol Dial Transplant; 1996 Jan; 11(1):165-72. PubMed ID: 8649628
[TBL] [Abstract][Full Text] [Related]
20. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation.
Canadian Neoral Renal Transplantation Study Group
Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
